NASDAQ:NTRA

Natera - NTRA Stock Forecast, Price & News

$41.84

+0.59 (+1.43%)

(As of 12/2/2022 12:00 AM ET)

Add

Compare

Today's Range: $39.90
▼
$42.18
50-Day Range: $34.17
▼
$47.91
52-Week Range: $26.10
▼
$98.70

Volume: 1.11 million shs
Average Volume: 2.18 million shs
Market Capitalization: $4.08 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $83.82

Natera MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 100.3% Upside
$83.82 Price Target
Short Interest: Healthy
5.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$797,832 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.68) to ($4.77) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

528th out of 1,034 stocks

Medical Laboratories Industry

13th out of 25 stocks

3.5

Analyst's Opinion

Consensus Rating
Natera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $83.82, Natera has a forecasted upside of 100.3% from its current price of $41.84.
Amount of Analyst Coverage
Natera has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.13% of the outstanding shares of Natera have been sold short.
Short Interest Ratio / Days to Cover
Natera has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Natera has recently decreased by 12.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Natera does not currently pay a dividend.
Dividend Growth
Natera does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NTRA.

2.5

News and Social Media Coverage

News Sentiment
Natera has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.31 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Natera this week, compared to 5 articles on an average week.
Search Interest
7 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $797,832.00 in company stock.
Percentage Held by Insiders
10.27% of the stock of Natera is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.95% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Natera are expected to grow in the coming year, from ($5.68) to ($4.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Natera is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Natera is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Natera has a P/B Ratio of 11.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Stock News Headlines

December 2, 2022 | americanbankingnews.com

Natera (NASDAQ:NTRA) Stock Price Up 7.1%

November 23, 2022 | finance.yahoo.com

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 21, 2022 | finance.yahoo.com

New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

November 10, 2022 | finance.yahoo.com

Natera Third Quarter 2022 Earnings: Beats Expectations

November 8, 2022 | finance.yahoo.com

Natera Reports Third Quarter 2022 Financial Results

November 4, 2022 | finance.yahoo.com

Natera (NTRA) Shares Outperformed in the Third Quarter on Positive Business Updates

November 2, 2022 | finance.yahoo.com

Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs

November 1, 2022 | finance.yahoo.com

Natera to Report its Third Quarter 2022 Results on November 8th

November 1, 2022 | finance.yahoo.com

Natera to Participate in Credit Suisse 31st Annual Healthcare Conference

October 26, 2022 | finance.yahoo.com

Natera, Inc. (NTRA)

October 17, 2022 | nasdaq.com

NTRA December 16th Options Begin Trading - Nasdaq

October 12, 2022 | proactiveinvestors.com

Naturally Splendid says Denny's renews agreement to provide Plantein plant-based Nuggets and Crumbed Tenders at all its restaurants across Canada - Proactive Investors USA

October 11, 2022 | seekingalpha.com

Natera: Cracks In The Bearish Trade

October 10, 2022 | reuters.com

Quest Diagnostics agrees to settlement of DNA-test patent dispute - Reuters

October 6, 2022 | finance.yahoo.com

New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer

October 4, 2022 | seekingalpha.com

Natera gains on publication of data on transplant rejection assessment test (NASDAQ:NTRA) - Seeking Alpha

October 4, 2022 | streetinsider.com

Natera (NTRA) Reports Study Showing Prospera Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection - StreetInsider.com

September 29, 2022 | finance.yahoo.com

Natera Announces 2025 ESG Goals with Publication of 2021 Report

September 12, 2022 | benzinga.com

Natera (NASDAQ:NTRA) – Natera Presents New Colorectal And Breast Cancer Data From The CIRCULATE-Japan Stu - Benzinga

September 12, 2022 | finance.yahoo.com

Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

September 8, 2022 | reuters.com

NTRA.O - Natera Inc | Stock Price & Latest News | Reuters

September 6, 2022 | benzinga.com

Natera Inc (NTRA) – Natera to Participate in Upcoming Investor Conferences - Benzinga

September 5, 2022 | nasdaq.com

Is Natera (NASDAQ:NTRA) Using Too Much Debt? - Nasdaq

September 1, 2022 | finance.yahoo.com

Hereditary Testing Market (Size, Volume, Share & Trends) — Report Comparison by Rating, ToC, Page Count, and Price only at Douglas Insights - Yahoo Finance

August 28, 2022 | reuters.com

NTRA.OQ - Natera Inc | Stock Price & Latest News | Reuters

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings: 11/04/2021
Today: 12/04/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/23/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NTRA
CUSIP: N/A
CIK: 1604821
Web: www.natera.com
Phone: (650) 249-9090
Fax: N/A
Employees: 2,670
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $83.82
High Stock Price Forecast: $110.00
Low Stock Price Forecast: $55.00
Forecasted Upside/Downside: +100.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-471,720,000.00
Net Margins: -70.34%
Pretax Margin: -70.27%
Return on Equity: -109.07%
Return on Assets: -48.98%

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 3.10
Quick Ratio: 2.95

Sales & Book Value

Annual Sales: $625.49 million
Price / Sales: 6.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.70 per share
Price / Book: 11.31

Miscellaneous

Outstanding Shares: 97,600,000
Free Float: 87,579,000
Market Cap: $4.08 billion
Optionable: Optionable
Beta: 1.29

Key Executives

Dr. Matthew Rabinowitz Ph.D. (Age 49)
Co-Founder & Exec. Chairman
Comp: $502.21k

Mr. Steven Leonard Chapman (Age 43)
CEO, Pres & Director
Comp: $925.59k

Mr. Michael B. Brophy M.B.A. (Age 42)
Chief Financial Officer
Comp: $661.5k

Mr. Robert A. Schueren (Age 60)
Chief Operating Officer
Comp: $706.72k

Mr. Daniel Rabinowitz L.L.M. (Age 53)
LL.M., Sec. & Chief Legal Officer
Comp: $557.47k

Mr. Jonathan Sheena M.Eng. (Age 49)
Co-Founder & Director

Ms. Olesya A. Anisimova CPA
Chief Accounting Officer

Mr. Rishi Kacker
Chief Technology Officer

Mr. Eric A. Evans
Chief Scientific Officer

Mr. Phil Grinnell
VP of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.
What is Natera's stock price forecast for 2023?: 6 Wall Street research analysts have issued 12 month price targets for Natera's stock. Their NTRA share price forecasts range from $55.00 to $110.00. On average, they predict the company's share price to reach $83.82 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.
How have NTRA shares performed in 2022?: Natera's stock was trading at $93.39 at the start of the year. Since then, NTRA stock has decreased by 55.2% and is now trading at $41.84.
View the best growth stocks for 2022 here.
When is Natera's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NTRA earnings forecast.
How were Natera's earnings last quarter?: Natera, Inc. (NASDAQ:NTRA) issued its earnings results on Thursday, November, 4th. The medical research company reported ($1.63) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by $0.36. The medical research company earned $158.10 million during the quarter, compared to analyst estimates of $151.92 million. Natera had a negative net margin of 70.34% and a negative trailing twelve-month return on equity of 109.07%. The company's quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.72) earnings per share.
What guidance has Natera issued on next quarter's earnings?: Natera updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $810.00 million-$830.00 million, compared to the consensus revenue estimate of $819.07 million.
What is Steve Chapman's approval rating as Natera's CEO?: 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).
When did Natera IPO?: (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
What is Natera's stock symbol?: Natera trades on the NASDAQ under the ticker symbol "NTRA."
Who are Natera's major shareholders?: Natera's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (9.00%), Vanguard Group Inc. (8.52%), State Street Corp (2.88%), Samlyn Capital LLC (2.33%), RTW Investments LP (2.26%) and Kynam Capital Management LP (2.07%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends.
How do I buy shares of Natera?: Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Natera's stock price today?: One share of NTRA stock can currently be purchased for approximately $41.84.
How much money does Natera make?: Natera (NASDAQ:NTRA) has a market capitalization of $4.08 billion and generates $625.49 million in revenue each year. The medical research company earns $-471,720,000.00 in net income (profit) each year or ($5.68) on an earnings per share basis.
How many employees does Natera have?: The company employs 2,670 workers across the globe.
How can I contact Natera?: Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 12/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial